On September 18, CSPC PHARMA rose 3.45% in regular trading, trading at HKD 9.175 per share, with turnover of HKD 142 million. The rally was primarily driven by the company's strong first-half earnings report released the prior day.

CSPC PHARMA reported H1 revenue of RMB 18.594 billion, up 40.1% year-over-year, with adjusted net profit attributable to shareholders surging 165.8% to RMB 6.164 billion from RMB 2.320 billion a year earlier. Gross margin expanded significantly from 65.6% to 76.2%, driven by a higher contribution from the finished drug business. Operating cash inflow reached RMB 10.89 billion versus RMB 3.187 billion in the prior-year period. Out-licensing revenue hit RMB 589 million, emerging as a key driver of the company's second growth curve.

The earnings release caps a period of intensive pipeline catalysts, including Breakthrough Therapy Designation for its EGFR ADC candidate SYS6010 in lung cancer and head-and-neck squamous cell carcinoma, Phase II trial initiations for diabetes and obesity drugs SYH2069, and FDA Fast Track designation for colorectal cancer candidate SYS6090.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)